A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning.

Objective: To compare sexual functioning in patients treated with quetiapine or risperidone.

Methods: This open-label study included patients with schizophrenia or a related psychotic illness who were randomized to quetiapine (200-1200 mg/d) or risperidone (1-6 mg/d) for 6 weeks. Sexual dysfunction was assessed by a semistructured interview, the Antipsychotics and Sexual Functioning Questionnaire (ASFQ), based upon the Utvalg for Kliniske Undersogelser (UKU).